Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast Asia
HONG KONG, Mar 31, 2023 - (ACN Newswire) - On 28th March 2023, Rxilient Biotech (a portfolio company of Legend Capital) and Junshi Biosciences made a joint announcement that two parties will form a joint venture to develop and commercialize toripalimab in Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam[1].From left to right: CEO of Junshi Biosciences,...
Source: asiaone.com
